Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting implications in oncology. FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which are believed to modulate tumor progression and immune response. Given its expression in tumors coupled with low expression in normal tissue, FAP has the potential to become an important biomarker for precision medicine in cancer. Already a focus of significant research by academics and the pharmaceutical industry, a FAP biomarker has potential to address unmet medical needs and to impact the clinical management of stroma-dense tumors, such as breast, colon, lung and pancreatic cancer.
Under terms of the agreement, Noria will drive the early clinical development of NTI-1309, leveraging its experience with early-stage imaging development. Upon completion of the Phase 1 study, NTI-1309 will be integrated into Lantheus’ portfolio of imaging biomarkers and included in the offering to academic centers and pharmaceutical companies for use in oncology drug development programs. Simultaneously,
“Lantheus is committed to advancing innovative imaging biomarker solutions to find, fight and follow cancer,” said
“The Noria team is excited to partner with a proven leader in imaging diagnostics with the experience and resources to advance this development program. Noria is pleased to have been entrusted by
Terms of the transaction include an upfront license and development fee to Noria, certain development and regulatory milestones, and royalties if NTI-1309 is commercialized.
About
About
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “believe,” “expect,” “intend,” “potential,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) expectations for future clinical trials, the timing and potential outcomes of clinical studies and filings and other interactions with regulatory authorities; (ii) the safety and efficacy of NTI-1309; (iii) regulatory risks related to NTI-1309; (iv) academic centers and pharmaceutical companies receptivity to NTI-1309 for use in oncology drug development programs; ; (v) the intellectual property protection of NTI-1309; (vi) our dependence upon third parties for the manufacture and supply of NTI-1309; and (vii) the risk and uncertainties discussed in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005613/en/
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com
Director, Corporate Communications
646-975-2533
media@lantheus.com
Source: